The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Which bispecific antibody should be used first in patients with myeloma?
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses a debate that focused on which bispecific antibody should be selected first when treating patients with multiple myeloma (MM). Although this decision is patient-specific, Dr Banerjee highlights the benefits of using the GPRC5D-targeting bispecific antibody talquetamab over BCMA-targeting antibodies, providing evidence for the drug’s superior efficacy, safety, and versatility. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
